Gyre Therapeutics Inc GYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
-
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Sidoti Events, LLC's Virtual August Micro-Cap Conference
-
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
-
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
-
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
-
Gyre Wins China Approval for Tablet to Treat Thrombocytopenia
Trading Information
- Previous Close Price
- $12.27
- Day Range
- $11.70–12.54
- 52-Week Range
- $4.80–30.40
- Bid/Ask
- $11.81 / $18.00
- Market Cap
- $1.10 Bil
- Volume/Avg
- 58,456 / 56,646
Key Statistics
- Price/Earnings (Normalized)
- 37.79
- Price/Sales
- 8.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 391
- Website
- https://www.gyretx.com
Comparables
Valuation
|
Metric
|
GYRE
|
TERN
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 37.79 | — | — |
Price/Book Value | 16.74 | 2.64 | 1.68 |
Price/Sales | 8.33 | — | — |
Price/Cash Flow | 52.76 | — | — |
Price/Earnings
GYRE
TERN
PLRX
Financial Strength
|
Metric
|
GYRE
|
TERN
|
PLRX
|
|---|---|---|---|
Quick Ratio | 2.78 | 20.57 | 14.21 |
Current Ratio | 3.22 | 21.02 | 14.47 |
Interest Coverage | — | — | −106.49 |
Quick Ratio
GYRE
TERN
PLRX
Profitability
|
Metric
|
GYRE
|
TERN
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | 20.54% | −28.87% | −27.65% |
Return on Equity (Normalized) | 72.98% | −30.36% | −31.11% |
Return on Invested Capital (Normalized) | 35.62% | −34.37% | −33.69% |
Return on Assets
GYRE
TERN
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vywqzpcww | Swwmn | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kgbzjdsvw | Gqbbtm | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nzptbshgj | Yxdkjp | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qxklpxc | Qnbpvv | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Svhmsvrw | Vyc | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Vfjzsdb | Ymyz | $28.3 Bil | |||
| Moderna Inc
MRNA
| Kvcgltybf | Jdrp | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Kcctdvrfq | Jbjq | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mcgbyxgb | Mngml | $13.3 Bil | |||
| Incyte Corp
INCY
| Zvrdxdl | Wyrglyq | $13.0 Bil |
United States